FCS Trial Navigator

Select Clinic:
Select Cancer Type:
Select Line of Therapy:
Select Trial Status:
Search Protocol Info:
ProtocolTitle
ABI-007-MBC-001
ABI-007-MBC-001
A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITAB ...
BP29262
GI 200
Phase 2, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 plus FOLFOX versus Bevacizumab plus FOLFOX in Patients with ...
BRE 250
BRE 250
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Asc ...
CUDC-907-101
HR 30
Phase I Open Label Multi-center, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CU ...
D4191C00001
LUN 282
Phase 3 Randomised, Double-Blind, Placebo-Controlled, Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable NSCLC w ...
GU 111
GU 111
GU 117
GU 117
Phase 2 Study of Mocetinostat in Selected Patients with Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advan ...
PCYC-1130-CA
CLL 34
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlo ...
RM 316
RM 316
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of A ...
RM 351
RM 351
A Phase 1b trial of LY2606368 in combination with either cisplatin or cetuximab in advanced or metastatic tumors
RM 376
RM 376
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Soli ...
391101
RM 269
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BAX69 IN SUBJECTS WITH MALIGNANT SOLID TUMORS
59R5-003
LUN 244
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer also now ...
ABI-007-MBC-001
BRE 223
Phase 2/3 Open-Label, Randomized Study of Weekly nab-Paclitaxel with Gemcitabine or Carboplatin Compared to Gemcitabine/Carboplatin as First Line Trea ...
ABI-007-NSCL-003
LUN 263
Phase 3, Randomized, Open-Label, Crossover Study to Evaluate Abraxane as Maintenance Treatment after Induction with Abraxane plus Carboplatin in Subje ...
AG221-C-001
HR 36
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-2 ...
BO25114
GI 185
Double-Blind, Placebo-Controlled, Randomized Phase 3 Study of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Her2-Positive Metastatic ...
BRE 200
BRE 200
Phase II Study of Cabazitaxel plus Lapatinib as Therapy for Her2-Positive Metastatic Breast Cancer Patients with Intracranial Metastases
BRE 212
BRE 212
A phase II open label study of everolimus in combination with anti-estrogen therapy in hormone receptor-positive HER2-negative advanced breast cancer
BRE 233
BRE 233
Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab E ...
BRE 240
BRE 240
Phase 2 Open-Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced ...
BVD-523-01
RM 286
PHASE I DOSE-ESCALATION, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF BVD-523 IN PATIENTS WITH ADVANCED MALIGNANCIES
C16014
C16014
This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of IXAZOMIB versus placebo when added to lenalidomi ...
C25003
LYM 84
A Randomized, Open-Label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma
C26002
GI 202
A phase 2 trial of MLN0264 in previously treated patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expr ...
C26003
GI 203
A phase 2 trial of MLN0264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)
C32496/1105
RM 309
An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients with Advanced Solid Tumors in Phase 1 and in Patients with Advanced Melano ...
CA209-153
LUN 272
Phase IIIb/IV Trial of Nivolumab in Advanced or Metastatic NSCLC Progressing During or After Receiving at Least One Prior Systemic Regimen
CDX011-04
BRE 231
Phase 2 Randomized Study of CDX-011 in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
CLL 18
CLL 18
Phase II Trial of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
CNS 13
CNS 13
Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma ...
CO-338-010
RM 259
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or O ...
COMETI-P2-2012.0
BRE 218
Phase 2 study of Characterization of CTCs from subjects with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
D2270C00005
BRE 196
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally ...
DLM-10-001
CNS 14
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of DAG in Patients With Recurrent Malignant Glioma
EMR200637-002
GI 197
Open Label, Randomized Phase 2 Trial Investigating Two Sym004 Doses versus Investigator's Choice in Metastatic Colorectal Cancer and Acquired Resistan ...
GI 194
GI 194
A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF nab®-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH ...
GO27802
BRE 220
A PHASE Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0032 IN COMBINATION WITH EITHER DOCETAXEL OR PACLITAXEL IN PATIENTS ...
GO27826
MEL 30
Phase III, Randomized, Double-Blind Placebo-Controlled study of Vemurafenib Adjuvant Therapy in Surgically Resected, Cutaneous BRAF-Mutant Melanoma at ...
GS-US-313-0124
LYM 85
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated I ...
GS-US-339-0102
LYM 89
A Phase 2 Open Label, Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Patients with Relapsed or Refractory Hem ...
GU 79
GU 79
Cabazitaxel with BKM120 in Patients with Metastatic Castrate-Resistant Prostate Cancer following Treatment with Docetaxel: Phase II Study with Safety ...
HR 34
HR 34
An Open-label, Phase 1 Study of Bendamustine (B), Rituximab (R) or BR in Combination with IPI-145 in Subjects With Select Relapsed or Refractory Hemat ...
HR 35
HR 35
A PHASE I OPEN-LABEL, MULTI-DOSE, DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
I3Y-MC-JPBL
BRE 248
A randomized, double- blind, placebo- controlled, Phase 3 study of fulvestrant with or without LY2835219, a CDK4/6 inhibitor, for post-menopausal wome ...
INCB18424-268
BRE 242
Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Her2-Negati ...
INCB18424-363
GI 199
Phase 3 Randomized, Double-Blind Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination with Capecitabine in Advanced or Metastatic Adeno ...
IPI-145-06
LYM 87
A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma
IPI-145-07
CLL30
Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
IPI-145-12
CLL 31
Study of IPI-145 and Ofatumumab in Patients with CLL/SLL Previously Enroll in IPI-145-07
LUN 214
LUN 214
Phase II Trial of Erlotinib and BKM120 in Patients with Advanced NSCLC Previously Sensitive to Erlotinib
LYM 98
LYM 98
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination with TGR-1202, a Novel PI3K Delta Inhibitor, ...
M12-194
M12-194
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative M ...
MDV3100-08
BRE 211
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (formerly MDV3100) in Patients w ...
MDV3100-12
BRE 229
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with A ...
MEL 41
MEL 41
A PHASE Ib, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED IN COMBINATION WITH VEMURAFENIB IN PATIENTS WITH PREVIOUSLY UNTR ...
MEL 47
CDX011-05
A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma https://clinicaltrials.gov/ct2/sh ...
ML28257
BRE 208
ML28257/BRE208 An Observational Study of Treatment Patterns and Outcomes in Patients with Her2 Positive Metastatic Breast Cancer
ML28897
PRO 02
Phase 2A Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or ...
MM 45
MM 45
A Multicenter, Randomized, Open-Label Non-comparative Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Relapsed and Refractory M ...
MM-302-02-02-03
BRE 249
Phase II, Randomized, Open-Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physicians Choice plus Trastuzumab in Anthracycline Naïve Patien ...
OMB113676
OMB113676
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Ri ...
PAC326
MPN 06
Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-PV Myelofibrosis, or ...
PAM4983g
RM 245
A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0068 IN COMBINATION WITH DOCETAXEL, FLUOROPYRIMIDINE PLUS OXALIPLA ...
PMT4979g
RM 275
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid ...
PPHM1202
LUN 264
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Bavituximab plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Stage IIIB/ ...
PR-30-5010-C
BRE 236
Phase 3, Randomized Trial of Niraparib versus Physician's Choice in Previously Treated Her2 Negative, BRCA Positive Breast Cancer
PR-30-5011-C
GYN 40
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
RM 187
RM 187
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Solid Malignancies Followed by a ...
RM 289
RM 289
An open-label, randomized, 2 treatment, 2-period, 2-way crossover, single-dose study to determine the relative bioavailability of the MEK inhibitor, t ...
RM 294
RM 294
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemoth ...
RM 312
RM 312
A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MS ...
RM 320
RM 320
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Me ...
RM 323
RM 323
A PHASE 1, FIRST-IN-HUMAN STUDY OF ESCALATING DOSES OF ORAL TVB 2640 IN PATIENTS WITH SOLID TUMORS
RM 345
RM 345
A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tum ...
RM 355
RM 355
A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF ORAL RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR ...
SCRx16-001
LUN 249
Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients with ...
SUP 03
SUP 03
A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500mg SC, Fosaprepitant 150mg IV, and Dexamethasone ...
TGR-1202-101
HR 31
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies
VS-4718-101
RM 307
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VS-4718 in Subjects with Metastatic Non- ...